Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers.
C L DeVane, J S Markowitz, S W Carson, D W Boulton, H S Gill, Z Nahas, S C Risch
Index: J. Clin. Psychopharmacol. 20(3) , 347-9, (2000)
Full Text: HTML
Abstract
Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.
Related Compounds
Related Articles:
2014-08-01
[Ther. Drug Monit. 36(4) , 528-34, (2014)]
2015-01-01
[PLoS ONE 10 , e0129805, (2015)]
2013-04-15
[Sci. Total Environ. 450-451 , 242-9, (2013)]
1992-01-01
[J. Pharm. Biomed. Anal. 10 , 187, (1992)]
1999-08-01
[J. Clin. Psychopharmacol. 19(4) , 362-6, (1999)]